Use of propyl thiouracil following recovery from thiouracil agranulocytosis.
SPRING
M
M
D000380:Agranulocytosis; D001500:BCG Vaccine; D001686:Biological Phenomena; D010829:Physiological Phenomena; D011441:Propylthiouracil; D013889:Thiouracil; D013890:Thiourea / Q000031:analogs & derivatives / Q000633:toxicity*; D014376:Tuberculosis
D001500:BCG Vaccine; D013889:Thiouracil; D011441:Propylthiouracil; D013890:Thiourea